A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

Please provide your email address to receive an email when new articles are posted on . Merkel cell carcinoma is often diagnosed after metastasis to other organs. However, new findings show those with ...

"Our study provides the first solid evidence that immunotherapy with pembrolizumab postsurgery may help people with Merkel ...

Merkel cell polyomavirus (MCPyV) and ambient ultraviolet radiation (UVR) exposure account for most Merkel cell carcinoma (MCC) cases in the United States. Researchers evaluated 38,020 MCC cases (38% ...

(PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, observed in the higher 15 mg/kg ...

TAMPA, Fla., June 24, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to ...

Investing.com -- Sensei Biotherapeutics Inc (NASDAQ:SNSE) stock fell 8.7% in premarket trading Friday after the company announced results from the dose expansion portion of its Phase 1/2 trial for its ...

Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC225Ac-SSO110 ...